عرض بسيط للتسجيلة

المؤلفSawalmeh, Osama
المؤلفMoala, Shaheed
المؤلفHamdan, Zakaria
المؤلفMasri, Huda
المؤلفAyoub, Khubaib
المؤلفKhazneh, Emad
المؤلفShraim, Mujahed
تاريخ الإتاحة2018-02-08T10:44:42Z
تاريخ النشر2018-01-15
اسم المنشورInternational Journal of Nephrology and Renovascular Disease
المعرّفhttp://dx.doi.org/10.2147/IJNRD.S149877
الاقتباسSawalmeh. el at. (2018) Pulse versus daily oral Alfacalcidol treatment of secondary hyperparathyroidism in hemodialysis patients: a randomized controlled trial. International Journal of Nephrology and Renovascular Disease. Volume 2018:11 , pp 25-32
معرّف المصادر الموحدhttp://hdl.handle.net/10576/6285
الملخصSecondary hyperparathyroidism is a common complication of chronic kidney disease and is managed using vitamin D replacement therapy. Very few studies have examined the effectiveness of pulse alfacalcidol therapy in comparison to daily oral alfacalcidol therapy in suppressing serum parathyroid hormone (PTH) levels in hemodialysis patients. The aim of this randomized controlled trial was to replicate the findings of prior studies comparing effectiveness of pulse oral alfacalcidol therapy versus daily oral alfacalcidol therapy in suppressing PTH after 13 weeks of therapy using a Palestinian sample of hemodialysis patients, and to identify demographic and biomedical characteristics of patients that are independently associated with PTH levels. One hundred and sixty-seven patients completed the study, 88 in the daily group and 79 in the pulse group. The pulse group had more clinically significant reduction in mean PTH level by 75 pg/dL at 13 weeks than the daily group, but this was not statistically significant. The effect of alfacalcidol therapy on metabolism of phosphate and corrected calcium levels was comparable in both groups, and pulse therapy was not associated with increased risk of hypercalcemia and hyperphosphatemia. Serum PTH levels were independently and inversely associated with older age and diabetes. Switching daily alfacalcidol therapy to thrice-weekly alfacalcidol pulse therapy seems safe and convenient, especially for hemodialysis patients with poor compliance with treatment. This study also highlights the importance of monitoring and preventing malnutrition in hemodialysis patients and maintaining optimal glycemic control in diabetic hemodialysis patients.
اللغةen
الناشرDove Medical Press
الموضوعalfacalcidol
end-stage kidney disease
hemodialysis
hyperparathyroidism
parathyroid hormone
pulse therapy
randomized controlled trials
العنوانPulse versus daily oral Alfacalcidol treatment of secondary hyperparathyroidism in hemodialysis patients: a randomized controlled trial.
النوعArticle
الصفحات25-32
رقم المجلد2018:11
ESSN1178-7058


الملفات في هذه التسجيلة

Thumbnail

هذه التسجيلة تظهر في المجموعات التالية

عرض بسيط للتسجيلة